Experience with ifosfamide in paediatric tumours
- 1 July 1989
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 24 (S1) , S28-S29
- https://doi.org/10.1007/bf00253235
Abstract
Ifosfamide, alone or in combination, is used in a variety of childhood tumours. Soft-tissue sarcomas are especially sensitive, with a 78% actuarial survival. Hyperaminoaciduria and a brief transient decrease in the plasma level of certain amino acids are the earliest signs of tubular toxicity.Keywords
This publication has 5 references indexed in Scilit:
- Ifosfamide in previously untreated disseminated neuroblastomaEuropean Journal of Cancer and Clinical Oncology, 1988
- POTENTIATION OF IFOSFAMIDE NEUROTOXICITY, HEMATOTOXICITY, AND TUBULAR NEPHROTOXICITY BY PRIOR CIS-DIAMMINEDICHLOROPLATINUM(II) THERAPY1987
- IFOSFAMIDE-INDUCED SUBCLINICAL TUBULAR NEPHROTOXICITY DESPITE MESNA1987
- Single-Agent Ifosfamide in Patients with Recurrent Neuroblastoma (Ensg Study 2)Pediatric Hematology and Oncology, 1987
- Ifosfamide, mesna and vincristine in paediatric oncologyCancer Treatment Reviews, 1983